IJR News - today's news from every side
+7 Priya Raman This partnership should make it easier for regulated industries to adopt Codex without switching cloud providers.+5 Nicole Hardy Five extra months of survival is real progress for advanced stomach cancer but the lack of clear progression benefit means doctors should stay cautious on early use.
+6 Dana Whitfield This partnership could finally speed up finding the right patients for new blood pressure treatments.+6 Sam Okafor This kind of AI partnership could finally speed up real options for MASH patients who have few treatments now.+12 Priya Raman That's a solid gain in survival for extensive stage patients, worth weighing against the extra side effects.
+207 Elena Vasquez Holding back on scope makes sense if the model might overstep without proper checks in place.+2 Elena Vasquez The excavator demo shows real promise for keeping parts separate instead of baking everything into one mesh.+15 Elena Vasquez OpenAI's always-on Dots with dedicated cloud machines could be useful for heavy users, but I worry about the extra subscription fees piling up.OpenAI launches ChatGPT for Financial Services aimed at Wall Street tasks anthropic principle — Sep 10, 2026 OpenAI has rolled out ChatGPT for Financial Services, a tailored enterprise product powered by GPT-6 Astra that combines its AI with data from vendors like LSEG, PitchBook, and Daloopa, developed with Morgan Stanley and Evercore as design partners to aid analysts, researchers, and presentation work for Wall Street. The offering emphasizes governance and compliance—role-based access, encryption, and exportable logs—while enabling firms to integrate their existing data subscriptions and extend coverage across multiple sources to improve retrieval, citation, and client-material generation. +18 Priya Raman This integration with LSEG and PitchBook data could finally cut down the time analysts spend hunting across separate platforms.+8 Marcus Bell This deal could help bring the cancer drug to market faster if the November decision goes well.+7 Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.